Search

Prezatide

Prezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions [A19503]. Prezatide is used in cosmetic products for the skin and hair. … It is known to aid wound healing and its potential applications in chronic obstructive pulmonary disease and metastatic colon cancer are currently being investigated.

Liotrix

It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. … Liotrix is a synthetically derived thyroid hormone replacement preparation.

Besifloxacin

Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.

Eflapegrastim

in which the patient develops an infection during a period of significant neutropenia. … [L43135] In September 2022, eflapegrastim was approved by the US FDA as a prophylactic against infection, as manifested by febrile neutropenia, in patients receiving certain myelosuppressive anti-cancer

Vilanterol

[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020. … Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma.

Selexipag

PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. … circulation and decrease elevated pressure in the blood vessels supplying blood to the lungs.

Danazol

It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. … A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins.

Fruquintinib

This approval is based on favorable results obtained from the FRESCO and FRESCO-2 trials, where an increase in overall survival rate was observed in both trials.[L48791] … Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis.

Mirikizumab

[L46237,L46257] Mirikizumab is approved in Japan[L46252] and received a positive opinion from the EMA's Committee for Medicinal Products for Human Use in March 2023. … Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis.

Calcium alginate